PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival - Rahbar, K; Boegemann, M; Yordanova, A (EJNMMI, 2018)
et al.